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ABSTRACT
Increasing the accuracy of self-sampling methods
to detect oncogenic human papillomavirus (HPV)
infection would contribute to the wider applica-
tion of these approaches. In this study, 120
women were tested for HPV-16 by conventional
and quantitative real-time PCR (QRT-PCR) in
cervical and self-sampled vaginal and urine spec-
imens. QRT-PCR had a higher detection rate, and
the HPV viral load in all three sampling sites
correlated with the severity of disease, as deter-
mined by histology. The vaginal and urine viral
loads correlated with HPV-16 positivity according
to both conventional and QRT-PCR, and were
proportional to the cervical viral load.
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Testing for human papillomavirus (HPV) using
molecular methods may be more sensitive than
cytology for primary cervical screening [1], and
self-sampling could significantly increase compli-
ance with preventive strategies. It has been
reported previously that HPV detection results
obtained using self-collected vaginal samples are
highly concordant with those obtained using
physician-collected cervical samples [2], while
urine testing is only useful for detecting severe
lesions [3]. In order to increase the detection rate,
the present study investigated the use of quanti-
tative real-time PCR (QRT-PCR), which is a
detection method that is considered to be more
sensitive than conventional PCR [4].
A previous large study revealed that the prob-
ability of an abnormal Pap test is directly propor-
tional to the HPV viral load [5]. High HPV viral
loads have also been associated with an increased
risk of developing cervical intra-epithelial neo-
plasia, even in smears with normal cytology [6–9],
and may predict the severity of cervical lesions
[10,11] and the presence of occult lesions [12].
These previous studies all used physician-
collected cervical specimens, which are currently
considered to be the reference standard. Since
self-sampling is increasingly being considered to
be a more convenient screening method, the
present study also investigated whether the viral
load in vaginal and urine specimens is associated
with more severe lesions, and whether it corre-
lates with results obtained using the conventional
cervical HPV test. Only one previous study has
measured viral loads in urine samples [13].
Following Institutional Review Board approval,
100 patients positive for HPV-16 (15 cancerous, 36
high-grade and 49 low-grade lesions) were
recruited from among women referred to the
colposcopy clinic. A further 20 patients with
normal cervical cytology were also recruited as
controls. A physician-collected cervical sample
was taken from all women for HPV testing before
they had a colposcopy. Before the pelvic exami-
nation, all women collected a self-sampled vagi-
nal specimen by rotating a soft endocervical
collection brush four times in the vagina, and
also provided a first void urine specimen [2,3].
Initial qualitative detection of HPV-16 was
performed using a conventional PCR protocol,
while the HPV-16 viral load was determined
using QRT-PCR. The primers used were specific
for the E1 or E6 genes [2,3,11]. The E6 primer set
performed best in conventional PCRs, and the E1
primer set performed best in QRT-PCR; the
respective results were used for comparison of
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the methods. Viral copy numbers in each sample
were calculated by comparing the QRT-PCR
results with a standard curve for HPV-16, created
using ten-fold serial dilutions of a plasmid DNA
standard, equivalent to 107–101 copies of HPV-16
DNA. Viral loads were determined in duplicate,
with mean values expressed as HPV copies ⁄lg of
total DNA.
In all patients, the viral load values in cervical
specimens were higher or equal to those in
vaginal specimens, which were higher or equal
to those in urine specimens (Table 1). In cancer
cases, the viral load in the cervical specimens was
considerably higher (median ten-fold) than that in
the vaginal specimens, and was even higher
(median 42-fold) than that in urine specimens.
The viral load difference was less pronounced
between high- and low-grade lesions. Further-
more, the median HPV viral load increased
significantly in line with the increased severity
of cytopathological changes in cervical (p <0.001),
vaginal (p <0.003) and urine (p <0.001) specimens
(Table 1). Such a correlation has been reported
previously only for cervical samples [6–12], but
no previous study has tested all three sampling
sites simultaneously.
The application of QRT-PCR improved the
performance of both self-sampling methods for
all histological classes (Table 2). When the per-
formance of QRT-PCR was compared with that of
conventional PCR, the vaginal QRT-PCR had the
highest sensitivity, followed by conventional vag-
inal PCR, urine QRT-PCR and conventional urine
PCR (Table 2). The kappa measure of agreement
with the cervical PCR was 0.625 (standard error
(SE) 0.082) for the conventional vaginal PCR, and
0.816 (SE 0.066) for the vaginal QRT-PCR. For the
urine specimens, the conventional PCR had a
kappa value of 0.289 (SE 0.067), compared with
a kappa value of 0.362 (SE 0.059) for the QRT-
PCR.
Regression analysis revealed that HPV-16 viral
loads in cervical specimens correlated with those
in vaginal samples and urine (data not shown). A
significant correlation (p <0.05) was also found
between increased viral loads in the cervical
specimens and enhanced sensitivity of HPV-16
detection using both self-sampling methods. The
positive self-sampling specimens correlated with
higher cervical viral loads, which are considered
to be an ominous prognostic sign [5–9]. Discor-
dant results between positive cervical and nega-
tive vaginal and urine samples often showed low
viral loads, usually <6000 copies ⁄ lg of DNA.
Women with low viral loads are more likely to
clear their HPV infections than those with higher
viral loads [6]. Therefore, from a clinical view-
point, it would probably be of greater value to
refer patients with a high viral load to a specialist.
The present data indicate that women at high risk
Table 1. Viral load (copies ⁄lg
DNA) in different specimens,
grouped according to the histologi-
cal classification
Minimum 25% Median 75% Maximum
A. Viral load—cervix (p <0.001)
Low grade (n = 49) 2245 6040 26 366 64 775 6 994 554
High grade (n = 36) 3077 46 048 123 678 1 199 321 9 182 746
Cancer (n = 15) 94 110 210 408 779 344 2 641 284 7 558 141
B. Viral load—vagina (p <0.003)
Low grade (n = 49) 0 5238 16 653 87 332 984 650
High grade (n = 36) 0 5105 20 503 257 487 912 387
Cancer (n = 15) 13 302 31 484 78 835 188 952 838 045
C. Viral load—urine (p <0.001)
Low grade (n = 49) 0 0 0 13 155 356 478
High grade (n = 36) 0 2 945 6 580 40 046 66 444
Cancer (n = 15) 0 7640 18 200 42 220 177 530
Table 2. Comparison between results obtained using conventional and QRT-PCR detection with self-sampled specimens
(vaginal and urine) and results obtained with cervix specimens from 100 HPV-16 cervical-positive patients with proven
abnormal histology (by cone or colposcopically-directed biopsy)
Cervix
PCR-positive, n
Vaginal PCR sensitivity,
n (%) (95% CI)
Urine PCR sensitivity,
n (%) (95% CI)
Vaginal QRT-PCR
sensitivity, n (%)
(95% CI)
Urine QRT-PCR
sensitivity, n (%)
(95% CI)
Cancer 15 14 (93.3) (68.1–99.8) 13 (86.7) (59.5–98.3) 15 (100) (78.2–100) 14 (93.3) (68.1–99.8)
High grade 36 33 (91.7) (77.5–98.2) 26 (72.2) (54.8–85.8) 35 (97.2) (85.5–99.9) 30 (83.3) (67.2–93.6)
Low grade 49 38 (77.6) (63.4–88.2) 16 (32.7) (19.9–47.5) 43 (87.8) (75.2–95.4) 19 (38.8) (25.2–53.8)
Total positive 100 85 (85.0) (76.5–91.4) 55 (55.0) (47.5–65.0) 93 (93.0) (86.1–97.1) 63 (63.0) (52.8–72.4)
QRT-PCR, quantitative real-time PCR.
620 Clinical Microbiology and Infection, Volume 14 Number 6, June 2008
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 605–624
could be identified accurately using QRT-PCR in
conjunction with self-sampled specimens (vagina
or urine) as an alternative to cytological screening
and ⁄ or cervical viral load measurement [14].
Qualitative real-time (RT)-PCR protocols for
HPV typing are also available and have high
sensitivity. In this context, a two-step approach,
involving HPV typing by qualitative RT-PCR and
measurement of type-specific viral loads only in
high-risk HPV-positive self-sampled specimens,
would probably be more cost-effective. As the
costs of both qualitative and QRT-PCRs for HPV-
16 are expected to gradually reduce, and given
their higher analytical sensitivity, implementation
of the more convenient self-sampling strategy is
possible. However, clinical viral load thresholds
should be defined and the methods used should
be validated in larger populations and standar-
dised with control panels [15].
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